Karyopharm collects $20M in first funding round
Stealthy pharmaceutical startup Karyopharm Therapeutics Inc., born out of the ashes of Epix Pharmaceuticals, has raised a $20 million Series A financing round from unnamed backers, officials said.
The Newton-based company is focusing on the new field of nuclear transport modulators, a broad-reaching mechanism that regulates many of the molecules associated with many diseases in both humans and animals. Specifically, they are looking to stop the mechanism that allows nucleus material to be exported out of a diseased cell, which happens when viruses replicate, or tumors grow. Keeping the diseased cell from exporting its nuclear material will cause it to die, without affecting nearby healthy cells, officials said.